bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
bioAffinity Technologies (Nasdaq: BIAF; BIAFW), a biotechnology firm, announced that the Australian Patent Office has accepted its patent application for a method of predicting lung cancer using the CyPath® Lung diagnostic test. This patent, titled “Detection of Early-Stage Lung Cancer in Sputum Using Automated Flow Cytometry and Machine Learning,” adds to the company's existing portfolio of 17 awarded U.S. and foreign patents and 38 pending applications. The Australian patent, set to expire in 2042, will be the second awarded for the CyPath® Lung test as a stand-alone assay for lung cancer detection.
The acceptance is seen as a milestone that enhances bioAffinity's market reach and strengthens its potential to improve lung cancer outcomes through earlier detection. The patent will be automatically issued three months after acceptance unless a third party files an opposition. The company believes this intellectual property protection will benefit patients, physicians, shareholders, and the company.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW), una società biotecnologica, ha annunciato che l'Ufficio Brevetti Australiano ha accettato la sua domanda di brevetto per un metodo di previsione del cancro ai polmoni utilizzando il test diagnostico CyPath® Lung. Questo brevetto, intitolato “Rilevamento del Cancro ai Polmoni in Fase Iniziale nel Sangue Feco usando la Citometria a Flusso Automatica e l'Apprendimento Automatico,” si aggiunge al portafoglio esistente dell'azienda di 17 brevetti concessi negli Stati Uniti e all'estero e 38 domande pendenti. Il brevetto australiano, che scadrà nel 2042, sarà il secondo concesso per il test CyPath® Lung come saggio autonomo per la rilevazione del cancro ai polmoni.
L'accettazione è vista come un traguardo che amplia la portata di mercato di bioAffinity e rafforza il potenziale della società di migliorare i risultati nel cancro ai polmoni attraverso una rilevazione più tempestiva. Il brevetto sarà automaticamente rilasciato tre mesi dopo l'accettazione, a meno che una terza parte non presenti un'opposizione. L'azienda ritiene che questa protezione della proprietà intellettuale porterà benefici ai pazienti, ai medici, agli azionisti e alla società.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW), una empresa de biotecnología, anunció que la Oficina de Patentes de Australia ha aceptado su solicitud de patente para un método de predicción del cáncer de pulmón utilizando la prueba diagnóstica CyPath® Lung. Esta patente, titulada “Detección de Cáncer de Pulmón en Etapas Tempranas en Esputo Usando Citometría de Flujo Automatizada y Aprendizaje Automático,” se suma a la cartera existente de la compañía de 17 patentes otorgadas en EE. UU. y en el extranjero, y 38 solicitudes pendientes. La patente australiana, que vencerá en 2042, será la segunda concedida para la prueba CyPath® Lung como un ensayo independiente para la detección del cáncer de pulmón.
La aceptación se ve como un hito que amplía el alcance del mercado de bioAffinity y fortalece su potencial para mejorar los resultados del cáncer de pulmón a través de una detección temprana. La patente se emitirá automáticamente tres meses después de la aceptación, a menos que una tercera parte presente una oposición. La empresa cree que esta protección de propiedad intelectual beneficiará a los pacientes, médicos, accionistas y a la compañía.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW), 생명공학 회사는 호주 특허청이 CyPath® Lung 진단 테스트를 사용하여 폐암을 예측하는 방법에 대한 특허 출원을 수락했다고 발표했습니다. “자동 흐름 세포 측정법 및 기계 학습을 사용한 가래에서의 조기 폐암 탐지”라는 제목의 이 특허는 미국 및 해외에서 17개의 부여된 특허와 38개의 청원 중인 신청서로 이루어진 회사의 기존 포트폴리오에 추가됩니다. 2042년에 만료될 호주 특허는 폐암 탐지를 위한 독립형 검사로서 CyPath® Lung 검사에 대해 두 번째로 부여된 것입니다.
이 수락은 bioAffinity의 시장 범위를 확장하고 조기 탐지를 통해 폐암 결과를 개선할 가능성을 강화하는 이정표로 간주됩니다. 특허는 제3자가 이의 제기를 제기하지 않는 한 수락 후 3개월 만에 자동으로 발급됩니다. 회사는 이 지식 재산 보호가 환자, 의사, 주주 및 기업에 혜택을 줄 것이라고 믿고 있습니다.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW), une entreprise de biotechnologie, a annoncé que l'Office australien des brevets a accepté sa demande de brevet pour une méthode de prédiction du cancer du poumon utilisant le test diagnostique CyPath® Lung. Ce brevet, intitulé “Détection d'un cancer du poumon à un stade précoce dans les crachats par cytométrie en flux automatisée et apprentissage automatique,” s’ajoute au portefeuille existant de l’entreprise comprenant 17 brevets délivrés aux États-Unis et à l'étranger, ainsi que 38 demandes en attente. Le brevet australien, qui expirera en 2042, sera le deuxième accordé pour le test CyPath® Lung en tant qu'essai indépendant pour la détection du cancer du poumon.
L'acceptation est considérée comme une étape importante qui élargit la portée de marché de bioAffinity et renforce son potentiel d'amélioration des résultats en matière de cancer du poumon grâce à une détection précoce. Le brevet sera automatiquement délivré trois mois après son acceptation, à moins qu'une tierce partie ne formule une opposition. L'entreprise estime que cette protection de la propriété intellectuelle sera bénéfique pour les patients, les médecins, les actionnaires et l'entreprise.
bioAffinity Technologies (Nasdaq: BIAF; BIAFW), ein Biotechnologieunternehmen, gab bekannt, dass das Australische Patentamt seinen Patentantrag für ein Verfahren zur Vorhersage von Lungenkrebs mithilfe des CyPath® Lung Diagnosetests angenommen hat. Dieses Patent mit dem Titel „Erkennung von Lungenkrebs im Frühstadium im Sputum unter Verwendung automatisierter Durchflusszytometrie und maschinellen Lernens“ erweitert das bestehende Portfolio des Unternehmens um 17 erteilte US-amerikanische und ausländische Patente sowie 38 ausstehende Anträge. Das australische Patent, das im Jahr 2042 abläuft, wird das zweite für den CyPath® Lung-Test als eigenständigen Test zur Lungenkrebsdiagnose sein.
Die Annahme wird als ein Meilenstein angesehen, der die Marktpräsenz von bioAffinity erweitert und das Potenzial stärkt, die Ergebnisse von Lungenkrebs durch eine frühere Erkennung zu verbessern. Das Patent wird automatisch drei Monate nach der Annahme erteilt, es sei denn, eine dritte Partei legt einen Einspruch ein. Das Unternehmen ist der Meinung, dass dieser Schutz des geistigen Eigentums den Patienten, Ärzten, Aktionären und dem Unternehmen zugutekommen wird.
- Australian Patent Office's acceptance of the patent application.
- Patent strengthens bioAffinity's market position and potential for early lung cancer detection.
- Patent adds to an existing portfolio of 17 awarded patents and 38 pending applications.
- Patent set to expire in 2042, providing long-term protection.
- Patent issuance could be delayed if a third party files an opposition.
Insights
The Australian Patent Office's acceptance of bioAffinity's patent application represents a strategic expansion of their intellectual property protection for CyPath® Lung. This patent, set to expire in 2042, provides nearly two decades of market exclusivity in Australia, a significant healthcare market with approximately 13,000 new lung cancer cases annually.
The patent acceptance is particularly valuable as it marks the second jurisdiction to recognize their flow cytometry and machine learning methodology. This strengthens bioAffinity's position in two key ways: First, it validates their technology's novelty and innovation across multiple patent offices. Second, it creates a potential barrier to entry for competitors in the Australian market, which could be leveraged for licensing opportunities or direct market entry.
However, investors should note that the patent is not yet fully secured - there's a three-month opposition period where third parties can challenge the patent's validity. Additionally, while patent protection is important for biotech companies, it doesn't guarantee commercial success. The company still needs to navigate regulatory approvals and market adoption to monetize this intellectual property effectively.
The Australian patent application, titled “Detection of Early-Stage Lung Cancer in Sputum Using Automated Flow Cytometry and Machine Learning,” will be an important addition to bioAffinity Technologies’ patent portfolio, which includes 17 awarded
“Lung cancer is a global problem that requires global solutions like our noninvasive diagnostic CyPath® Lung that detects the leading cancer-killer at early stage when treatment can lead to cures. The Australian patent is another milestone that increases our market and strengthens our potential to improve the outcome for lung cancer patients around the globe through earlier detection,” bioAffinity Technologies President and CEO Maria Zannes said. “Strong intellectual property protection for CyPath® Lung benefits not only patients and their physicians, but also our shareholders and our Company.”
The
About CyPath® Lung
CyPath® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the Australian patent being an important addition to bioAffinity Technologies’ patent portfolio. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, a third party filing an opposition to the automatic granting of the patent and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122586375/en/
bioAffinity Technologies
Julie Anne Overton
Director of Communications
jao@bioaffinitytech.com
Investor Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498
BIAF@redchip.com
Source: bioAffinity Technologies, Inc.
FAQ
What is the significance of the Australian patent acceptance for BIAF?
When will the Australian patent for CyPath® Lung be issued?
How many patents does bioAffinity Technologies currently hold?
What is the title of the newly accepted Australian patent for BIAF?
What is the expiration date of the new Australian patent for BIAF?
What does the new patent mean for BIAF shareholders?
